These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36168659)

  • 1. Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
    Nirogi R; Jayarajan P; Benade V; Shinde A; Goyal VK; Jetta S; Ravula J; Abraham R; Grandhi VR; Subramanian R; Pandey SK; Badange RK; Mohammed AR; Jasti V; Ballard C; Cummings J
    Int J Geriatr Psychiatry; 2022 Oct; 37(10):. PubMed ID: 36168659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
    Nirogi R; Ieni J; Goyal VK; Ravula J; Jetta S; Shinde A; Jayarajan P; Benade V; Palacharla VRC; Dogiparti DK; Jasti V; Atri A; Cummings J
    Alzheimers Dement (N Y); 2022; 8(1):e12307. PubMed ID: 35662833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.
    Nirogi R; Goyal VK; Benade V; Subramanian R; Ravula J; Jetta S; Shinde A; Pandey SK; Jayarajan P; Jasti V; Cummings J
    Neurol Ther; 2022 Dec; 11(4):1583-1594. PubMed ID: 35908254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
    Herrmann N; Gauthier S; Boneva N; Lemming OM;
    Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial.
    Devanand DP; Crocco E; Forester BP; Husain MM; Lee S; Vahia IV; Andrews H; Simon-Pearson L; Imran N; Luca L; Huey ED; Deliyannides DA; Pelton GH
    Am J Geriatr Psychiatry; 2022 Jan; 30(1):32-42. PubMed ID: 34059401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
    Cummings JL; Schneider E; Tariot PN; Graham SM;
    Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
    Ostinelli EG; Hussein M; Ahmed U; Rehman FU; Miramontes K; Adams CE
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD009412. PubMed ID: 29634083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
    De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
    J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
    Sommer OH; Aga O; Cvancarova M; Olsen IC; Selbaek G; Engedal K
    Dement Geriatr Cogn Disord; 2009; 27(2):155-63. PubMed ID: 19182483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
    Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
    Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.